Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Ordinary Shares, no par value
-
Shares outstanding
-
156M
-
Number of holders
-
174
-
Total 13F shares, excl. options
-
139M
-
Shares change
-
+7.83M
-
Total reported value, excl. options
-
$903M
-
Value change
-
+$46.4M
-
Put/Call ratio
-
0.07
-
Number of buys
-
106
-
Number of sells
-
-77
-
Price
-
$6.50
Significant Holders of Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) as of Q2 2025
227 filings reported holding WVE - Wave Life Sciences Ltd. - Ordinary Shares, no par value as of Q2 2025.
Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) has 174 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 139M shares
of 156M outstanding shares and own 89.29% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (18.2M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (15M shares), BlackRock, Inc. (10.4M shares), MAVERICK CAPITAL LTD (8.26M shares), Driehaus Capital Management LLC (6.53M shares), M28 Capital Management LP (5.66M shares), PRICE T ROWE ASSOCIATES INC /MD/ (5.19M shares), Kynam Capital Management, LP (4.56M shares), 683 Capital Management, LLC (4.1M shares), and Bellevue Group AG (4.09M shares).
This table shows the top 174 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.